SCHEMBL5505024

SCHEMBL5505024

NCCC(F)(F)S(=O)(=O)O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
SLC6A6 P31641 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
APP P05067 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADRB3 P13945 1/20 0.32
FDPS P14324 1/20 0.32
PDE4D Q08499 1/20 0.32
PDE3A Q14432 1/20 0.32
HDAC6 Q9UBN7 1/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA7 P43166 1/20 0.30
CA13 Q8N1Q1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL21239998 0.76 ALDH1A1 (0.36) LMNASLC6A6CYP2C19BLMAPP
SCHEMBL2759440 0.76 ALDH1A1 (0.36) ALDH1A1L3MBTL1
SCHEMBL28620962 0.76 ALDH1A1 (0.36) ALDH1A1L3MBTL1
Trifluoromethanesulfonic Acid SCHEMBL28056248 0.75 BLM (0.43) LMNASLC6A6CYP2C19BLMAPP
SCHEMBL3871127 0.74 LPAR1 (0.35) ALDH1A1L3MBTL1FDPS
SCHEMBL28621293 0.74 ALDH1A1 (0.35) ALDH1A1L3MBTL1
Ammonia Solution, Strong SCHEMBL28620997 0.74 ALDH1A1 (0.35) ALDH1A1L3MBTL1
Dimethylamine SCHEMBL18008050 0.73 EPHX1 (0.35) ALDH1A1L3MBTL1
Dimethylamine SCHEMBL28635368 0.73 ALDH1A1 (0.31) ALDH1A1L3MBTL1
SCHEMBL5031182 0.72 PTGS1 (0.36) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311860-A1 METHOD FOR MAKING PROTON CONDUCTING MEMBRANES FOR FUEL CELLS BY RADIOGRAFTING COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-12-09 US disclosed
US-20100311860-A1 METHOD FOR MAKING PROTON CONDUCTING MEMBRANES FOR FUEL CELLS BY RADIOGRAFTING COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-12-09 US disclosed
US-20100304273-A1 PROTON CONDUCTING MEMBRANES FOR FUEL CELLS HAVING A PROTON GRADIENT AND METHODS FOR PREPARING SAID MEMBRANES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-12-02 US disclosed
US-20100304273-A1 PROTON CONDUCTING MEMBRANES FOR FUEL CELLS HAVING A PROTON GRADIENT AND METHODS FOR PREPARING SAID MEMBRANES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-12-02 US disclosed
WO-2009040362-A1 PROTON CONDUCTING MEMBRANES FOR FUEL CELLS HAVING A PROTON GRADIENT AND METHOD FOR PREPARING SAID MEMBRANES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2009-04-02 WO disclosed
WO-2009040365-A1 METHOD FOR MAKING PROTON CONDUCTING MEMBRANES FOR FUEL CELLS BY RADIOGRAFTING COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2009-04-02 WO disclosed
EP-1828111-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2007-09-05 EP disclosed
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed
WO-2006059252-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR LMNA 50/4885SLC6A6 2124/4885CYP2C19 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.